2016
DOI: 10.1002/prp2.280
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacokinetics and pharmacodynamics of antibiotics in critically ill acute kidney injury patients

Abstract: Sepsis is the most common cause of death in critically ill patients and is associated with multiorgan failure, including acute kidney injury (AKI). This situation can require acute renal support and increase mortality. Therefore, it is essential to administer antimicrobials in doses that achieve adequate serum levels, avoiding both overdosing and drug toxicity as well as underdosing and the risk of antibiotic resistance and higher mortality. Currently, there are no validated guidelines on antibiotic dose adjus… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
39
0
3

Year Published

2019
2019
2023
2023

Publication Types

Select...
8

Relationship

3
5

Authors

Journals

citations
Cited by 33 publications
(44 citation statements)
references
References 30 publications
1
39
0
3
Order By: Relevance
“…Despite having the availability to realize therapeutic monitoring of the drug, which is not unanimous in all centers, difficulties have been observed with reaching and sustaining adequate serum concentrations, due to factors related to collection, patients, and pharmacokinetic variation of the drug in septic patients. 8 In our study, this Notes: *Mean ± SD. T0-T2, serum concentration between the start and second day of usage of vancomycin (0-48 hours); T2-T4: serum concentration between the second and fourth days of usage of vancomycin (48-96 hours); T4-T6: serum concentration between the fourth and sixth days of usage of vancomycin (96-144 hours); T6-T8: serum concentration between the sixth and eighth days of usage of vancomycin (144-192 hours difficulty was also present, with elevated rates of subtherapeutic and toxic concentrations.…”
Section: Discussionmentioning
confidence: 57%
See 1 more Smart Citation
“…Despite having the availability to realize therapeutic monitoring of the drug, which is not unanimous in all centers, difficulties have been observed with reaching and sustaining adequate serum concentrations, due to factors related to collection, patients, and pharmacokinetic variation of the drug in septic patients. 8 In our study, this Notes: *Mean ± SD. T0-T2, serum concentration between the start and second day of usage of vancomycin (0-48 hours); T2-T4: serum concentration between the second and fourth days of usage of vancomycin (48-96 hours); T4-T6: serum concentration between the fourth and sixth days of usage of vancomycin (96-144 hours); T6-T8: serum concentration between the sixth and eighth days of usage of vancomycin (144-192 hours difficulty was also present, with elevated rates of subtherapeutic and toxic concentrations.…”
Section: Discussionmentioning
confidence: 57%
“…6 The main polemic points on vancomycin relate to its efficacy and safety. [5][6][7][8][9] Regarding efficacy, the concern is the alteration in pharmacokinetics, usually related to the distribution, metabolism, and elimination of the drug, 6,8 which can lead to subtherapeutic concentrations, leading to the emergence of bacterial resistance due to the inefficacy of the treatment and consequently leading to higher mortality. Regarding safety, emphasis has been given to the main side effect of the medicationnephrotoxicitywhich can aggravate the clinical picture and contribute to unfavorable outcomes.…”
Section: Introductionmentioning
confidence: 99%
“…Vancomycin is a glycopeptide antimicrobial with antibacterial action, acting by inhibition of cell wall synthesis. It was introduced in clinical practice in the mid‐1950s for the treatment of bacterial infections caused by Gram‐positive bacteria and it is considered by the Infectious Disease Society of America (IDSA) as the first treatment option for methicillin‐resistant Staphylococcus aureus (MRSA) infections . However, it also presents action against Streptococcus pneumoniae , Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus bovis , Streptococcus viridans , Enterococcus , species of Clostridium , diphtheroids , Listeria monocitogenes , Actinomyces , and species of Lactobacillus .…”
Section: Vancomycinmentioning
confidence: 99%
“…Despite its wide use in clinical practice, there are unresolved concerns about its effectiveness and safety. Regarding efficacy, mainly in critically ill patients, its pharmacokinetics is altered, due to drug distribution, metabolism and elimination, which could lead to subtherapeutic serum concentration and develop bacterial resistance, with possible increased mortality . In terms of safety, its main side effect—nephrotoxicity—has been widely discussed, with risk of AKI and complications in the short and long term …”
Section: Vancomycinmentioning
confidence: 99%
“…A progressão da DRC pode levar a um quadro de uremia ou inadequado volume de diurese, casos em que os pacientes são encaminhados para a Terapia Renal Substitutiva (TRS) ou para transplante renal. Encontram-se disponíveis diferentes modalidades de TRS, como hemodiálise intermitente, TRS contínuas (que incluem técnicas de hemodiálise estendida como a Slow Low Efficient Dialysis (SLED), diálise peritoneal e, ainda, troca terapêutica do plasma [102,104,105].…”
Section: Doença Renal Crônicaunclassified